In a phase Ib multicenter, open-label study (NCT03625505) enrolling 61 patients with R/R AML harboring FLT3 mutations (ITD and/or TKD), the combination of VEN and gilteritinib yielded a high rate of response (CR + CRi, 75%). Here, FLT3 is linked to acute myeloid leukemia.